The oncology biotech Bolt Biotherapeutics has reduced its staff by half again in its second downsizing announcement in two years as the firm held back a readout of its lead immunotherapy.
The company had already anticipated early information of a phase 1 dose-escalation of an immune-stimulating antibody conjugate (ISAC) of Claudin 18.2 to treat gastric and gastroesophageal cancers in the first half of 2026. In an Oct. 1 postmarket release, the biotech clarified that it is already adjusting the trial protocol to permit step-up dosing step-by-step, raising the dose to the target level, after finding indications of a vigorous immune reaction at the early dose levels.
This, however, translates to the fact that the expected readout will be delayed to the third quarter of next year. The biotech has also been evaluating how to stretch the cash it currently has, which in this case is the $48.5 million that Bolt has carried over into June but will run out by mid-2026. The company has decided to reduce the rest of its workforce by half, which should keep the lights on until 2027.
In the release yesterday, Bolt CEO Willie Quinn said, “I would like to sincerely thank all of our colleagues who were affected by this decision. In the difficult market conditions, the clinical development of BDC-4812 and the development of our ISAC partnerships are our strategic imperatives, which would enhance shareholder value. We are optimistic about our future intention to pursue our mission and inform you about future updates regarding BDC-4812 next year.
At the close of 2024, Bolt had 52 employees remaining after this decision and another in August 2024 to cut the number of employees by half. The layoffs of last year had been associated with a strategic refocusing in which the company had stalled the development of a phase 2-stage ISAC named trastuzumab imbotolimod, being developed against HER2-positive cancer.
The biotech has ongoing collaborations with Genmab and Toray. Bolt also confirmed that it’s still hunting for a partner for its dectin-2 agonist antibody BDC-3042, which completed a phase 1 dose-escalation study earlier this year.
As Bolt moves forward, several critical questions will test its resilience and strategy. The step-up dosing approach for BDC-4812 will determine whether Bolt can control immune responses while maintaining therapeutic efficacy. A successful outcome could restore investor confidence and clinical momentum.
To strengthen its future, Bolt may also pursue strategic partnerships, particularly around BDC-3042, where early-stage data could attract interest from major oncology firms. Collaborations have long been part of Bolt’s model, and securing another alliance could extend funding and technical expertise through 2027.
Financial discipline remains key. With $48.5 million available, it must balance research ambitions with operational efficiency. The recent layoffs, while difficult, may represent a strategic effort to sustain the company through challenging markets rather than a retreat from innovation.
Ultimately, Bolt’s ability to stabilize operations, deliver meaningful clinical data, and maintain investor trust will decide whether it can rebound stronger. If successful, this leaner structure could set the stage for long-term growth and position Bolt as a persistent innovator in targeted immunotherapies.
Despite the difficulties of back-to-back layoffs, it’s leadership remains optimistic. The company’s focus on long-term sustainability over short-term growth could ultimately prove beneficial, particularly if the immunotherapy candidate demonstrates meaningful efficacy in gastric and gastroesophageal cancers. Success in these indications would place Bolt among the few mid-stage biotechs capable of driving innovation in antibody-conjugate technologies.
Looking forward, Bolt’s roadmap suggests a disciplined approach. The company is not only optimizing its clinical timelines but also re-evaluating its operational structure to support future expansion once capital markets stabilize. If the company can generate compelling clinical evidence and secure the right strategic partnerships, it may yet transform its recent challenges into a foundation for renewed growth.
